Ivan Kairatov brings a biopharma lens to one of the most sensitive decisions in pediatrics: when to give the first hepatitis B vaccine. With a research-and-development background rooted in tech and innovation, he translates probabilistic modeling, clinical epidemiology, and practical workflows into plain language. In this conversation, he unpacks why the first 24 hours matter, what happens when policies shift timing, how real-world adherence reshapes outcomes and costs, and which safety and immunogenicity signals should guide clinicians and families. Along the way, he reflects on modeling choices that likely underestimate downstream infections and dollars, and offers concrete steps birthing centers can take to deliver a reliable birth dose.
What motivated you to examine infant hepatitis B vaccine timing, and how did you prioritize outcomes like infections avoided, chronic disease prevented, and quality-adjusted life years? Can you share a moment or dataset that shifted your thinking during the project?
Two things drew me in: the first was the stark biology of perinatal hepatitis B, and the second was the policy whiplash from a universal birth dose to a selective approach. When a single timing decision can change the probability that a newborn ends up in the 90% who develop chronic infection after exposure—and that 25% will die prematurely of cirrhosis or liver cancer—you have to anchor on outcomes that matter: infections averted, chronic disease prevented, and gains in quality-adjusted life years. We weighted those outcomes alongside total costs because the models showed delays could translate into $16 million to $370 million in additional spending, depending on start age and adherence. The turning point was seeing side-by-side scenarios where delayed starts looked “cheaper” only if you assumed near-perfect completion; as soon as we relaxed that, the human and economic toll climbed quickly.
Newborns who acquire hepatitis B often develop chronic infection and face elevated lifetime mortality. How does that biology inform timing of the first dose, and what real-world cases or metrics best illustrate the stakes in the first 24 hours?
The biology is unforgiving in the first day of life. Infants’ immune systems, if exposed at birth, very often tolerate the virus rather than clear it—that’s why about 90% progress to chronic infection, with roughly a quarter facing premature death from cirrhosis or liver cancer. That’s the lens through which the 24-hour birth dose makes sense: it’s a shield put on before the first arrow flies. In practice, every missed day increases the window for exposure in delivery units, during early feeds, or at home; the most sobering metric is that universal within-24-hours dosing, recommended in 2018, was designed specifically to close that exposure window.
Some policies now delay the first dose for infants whose birth parent tests negative. What assumptions underlie that approach, and where do you see the biggest gaps between those assumptions and on-the-ground realities in hospitals and clinics?
That approach assumes perfect maternal screening, flawless documentation, and zero postnatal exposure outside of a known-positive parent. It also banks on families returning reliably for later doses. On the ground, labs result late, records don’t always follow a transferred patient, and babies go home to households and communities where hepatitis B can circulate, especially if more people remain susceptible. The biggest gap is the belief that low incidence is “ambient”; in truth, low incidence in the United States is a dividend from vaccination programs—dial back protection and that dividend erodes.
Your scenarios contrasted birth dosing with starting at 2 months, 7 months, 4 years, or 12 years. Which ages drive the steepest increases in risk, and why? Can you walk through the mechanisms and any age-specific exposure patterns you tracked?
The steepest risk jump comes with pushing the first dose beyond the immediate newborn period because you lose perinatal protection altogether. Starting at 2 months already exposes infants to early-life contacts unprotected; at 7 months and 4 years, mobility, daycare, and sibling interactions layer on more opportunities. Deferring to 12 years places kids into adolescence still susceptible, which adds behavioral exposures on top of household ones. Mechanistically, each delay intersects with different contact networks, and our models showed that the longer the delay, the more infections and chronic sequelae accumulated, especially when completion wasn’t perfect.
You estimated additional health care costs ranging from tens to hundreds of millions, depending on delay and adherence. What line items dominate those costs over time, and how should health departments or insurers budget for them?
Downstream costs are dominated by managing chronic infection and its complications—monitoring, antiviral therapy, and treatment of cirrhosis and liver cancer. Hospitalizations and specialty care stack up, and once you cross into liver failure, the expenses escalate dramatically. In our projections, the aggregate burden ranged from $16 million to $370 million as timing slid from birth toward later ages and adherence waned. Budgeting-wise, I’d earmark funds in two buckets: up-front systems that guarantee the birth dose, and long-horizon reserves for chronic disease care if policies shift toward delay.
Many children never complete all three recommended doses, especially when the first dose is delayed. What completion rates did you assume across ages, and what step-by-step strategies actually raise series completion in busy pediatric practices?
We modeled both complete three-dose series and incomplete vaccination, because real life sits somewhere in between—and later starts consistently reduced completion probabilities. Rather than hang our hat on a single percentage, we ran adherence-sensitive scenarios to show how small drops cascade into bigger disease burdens. To raise completion, I recommend: standing orders that trigger the birth dose automatically; scheduling follow-up doses before discharge; EHR prompts tied to well-child visits; text reminders in the family’s preferred language; and end-of-day “huddle checks” that reconcile who’s due before the clinic closes. The earlier you start, the easier it is to keep momentum.
Household and community transmission can rise if more people remain susceptible. How would including those feedback loops change the projected infections and costs, and what surveillance or modeling tweaks would you add next?
Our estimates were conservative because they did not include increasing household or community transmission as susceptibility grows. If you let that feedback loop into the model, you’d see more secondary infections, more chronic cases, and a corresponding bump in costs beyond the $16 million to $370 million window. I’d move from static to dynamic transmission modeling, add household structure, and parameterize contact rates from early infancy through adolescence. On the surveillance side, linking birth records, vaccination registries, and lab-confirmed hepatitis B reports would let us recalibrate the model in near real time.
Safety concerns often drive calls to delay. Across decades of data, what adverse events have the strongest evidence base, what are their absolute risks, and how do you communicate that risk profile to hesitant parents in the delivery unit?
We reviewed four decades of studies, including comprehensive safety reviews, and found no evidence of serious adverse reactions—no signal for seizures, other neurological disorders, infections, or mortality attributable to the vaccine. That body of evidence, plus 35 years of immunogenicity data, undercuts the idea that delay brings a safety advantage. With parents, I keep it simple: the disease is common enough to affect 2.4 million people in the United States, newborns are the most vulnerable, and the vaccine given within 24 hours builds a durable shield with no credible evidence of severe harm. I acknowledge their worry, share the data calmly, and connect the decision to their baby’s first day at home when they want every layer of protection in place.
Long-term immunogenicity suggests durable protection after infant vaccination. What titers, waning patterns, or booster needs have you seen in cohorts followed into adolescence and adulthood, and how should clinicians interpret low anti-HBs levels years later?
Over 35 years of follow-up show long-term immunogenicity with likely lifetime protection for those vaccinated in infancy. Antibody levels can drift down, but protection doesn’t map one-to-one with circulating titers because immune memory stands ready to respond. When clinicians see low anti-HBs years later, the key is to remember that the original priming still matters; a low level isn’t the same as no protection. In the absence of exposure or special risk, the data don’t support a blanket benefit to delaying the first dose to chase some theoretical immunologic edge.
For birthing centers, what are the practical steps to ensure a consistent birth dose—ordering, EMR prompts, consent, cold chain, and bedside timing—and which pitfalls most often cause missed doses or delays?
Start with procurement: maintain par levels that cover weekends and holidays, and log lot numbers on receipt. Build EMR default orders for a within-24-hours dose for all infants, with clear workflows for exceptions. Standardize consent as part of the pre-delivery paperwork, confirm cold-chain integrity with daily logs, and place the vaccine physically on the postpartum unit so nurses aren’t hunting for it at 2 a.m. The usual pitfalls are simple: missing lab results, unclear responsibility at shift change, and “we’ll do it at discharge” plans that fall apart when families leave early.
In settings with unknown or late-arriving maternal hepatitis B status, what is your protocol for testing, prophylaxis, and vaccination timing? Can you outline a rapid pathway that prevents errors during off-hours and handoffs?
The pathway starts with ordering immediate maternal testing on arrival, but it never waits on the result to protect the newborn—we proceed with the birth dose within 24 hours. Use a standardized checklist that flags unknown status, assigns a single accountable clinician, and includes a second-person verification before discharge. Results, actions taken, and follow-up appointments are documented in the EMR and on a paper card handed to the family to bridge any digital gaps. Overnight, a laminated crib-side algorithm and a dedicated “stat vaccine” bin cut through delays when staffing is thin.
How do delays and incomplete vaccination magnify disparities across regions or populations with limited follow-up access? What metrics would you track to catch widening gaps early, and what outreach has proven to move the needle?
Delays shift protection away from the time families are most reliably in care—the birth hospitalization—and place more weight on future visits that are hardest for marginalized groups to make. That widens gaps in series completion and raises exposure risk at home and in the community. I’d watch on-time birth dose rates, completion of all three doses by key milestones, and incident pediatric hepatitis B cases stratified by geography and payer. Proven outreach includes scheduling before discharge, mobile reminders, community health workers who navigate transportation and language barriers, and partnerships with clinics that align vaccine visits with other essential services.
If policymakers weigh low current incidence against immediate cost savings, how should they evaluate the long-run trade-offs in chronic liver disease, cancer, and mortality? What decision framework or threshold analysis would you put in front of them?
I’d frame it as an intergenerational investment problem: today’s “savings” from delaying the birth dose convert into tomorrow’s chronic disease costs and premature deaths. A threshold analysis should vary adherence and start age to show when additional infections and chronic cases drive costs from $16 million up toward $370 million—and beyond if transmission feedback is included. Use quality-adjusted life years to capture lost survival and well-being, and present net health benefit side by side with budget impact over a multi-decade horizon. The crux is that low incidence is an achievement of vaccination; dismantling the front door of protection risks reversing that progress.
For clinicians counseling families who request a delay, what language, analogies, and data resonate without overwhelming them? Could you share a brief script that balances empathy with clear action steps?
I start with empathy: “You’re making a lot of decisions today; it’s normal to want to go slow.” Then I offer a clear analogy: “This vaccine is like buckling your baby’s seatbelt before the car moves—the first 24 hours are when protection matters most.” I share two numbers—the 90% chance of chronic infection after exposure in newborns and that about 25% of those with chronic infection die early from cirrhosis or liver cancer—and reassure them that decades of data show no evidence of serious adverse reactions. Script: “Let’s give the first dose now, within 24 hours, so your baby leaves with protection onboard. We’ll schedule the next visits before you go and send reminders so it’s easy.”
What is your forecast for hepatitis B prevention in the United States?
I’m cautiously optimistic if we hold the line on the birth dose and strengthen follow-up, because the pillars are strong: universal within-24-hours vaccination, three-dose completion, and vigilant surveillance. If selective policies expand and adherence slips, we’ll see preventable infections rise, more children progress to chronic disease, and costs climb from the tens into the hundreds of millions. The science is steady—35 years of immunogenicity and no evidence of serious safety signals—and the path to elimination still runs through that first day of life. My forecast: maintain universal birth dosing, invest in adherence systems, and we keep incidence low; chip away at either, and we start paying in chronic liver disease and lost lives.
